Skeletal Biotech Laboratory, The Hebrew University-Hadassah Faculty of Dental Medicine, Ein Kerem, 91120, Jerusalem, Israel.
Department of Surgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd., AHSP-8304, Los Angeles, CA, 90048, USA.
Curr Osteoporos Rep. 2018 Aug;16(4):504-511. doi: 10.1007/s11914-018-0459-3.
The purpose of this review is to discuss the recent advances in gene therapy as a treatment for bone regeneration. While most fractures heal spontaneously, patients who present with fracture nonunion suffer from prolonged pain, disability, and often require additional operations to regain musculoskeletal function.
In the last few years, BMP gene delivery by means of electroporation and sonoporation resulted in repair of nonunion bone defects in mice, rats, and minipigs. Ex vivo transfection of porcine mesenchymal stem cells (MSCs) resulted in bone regeneration following implantation in vertebral defects of minipigs. Sustained release of VEGF gene from a collagen-hydroxyapatite scaffold to the mandible of a human patient was shown to be safe and osteoinductive. In conclusion, gene therapy methods for bone regeneration are systematically becoming more efficient and show proof-of-concept in clinically relevant animal models. Yet, on the pathway to clinical use, more investigation is needed to determine the safety aspects of the various techniques in terms of biodistribution, toxicity, and tumorigenicity.
本文旨在讨论基因治疗在骨再生治疗中的最新进展。虽然大多数骨折可以自行愈合,但骨折不愈合的患者会长期疼痛、残疾,通常需要额外的手术来恢复肌肉骨骼功能。
在过去几年中,电穿孔和超声穿孔介导的 BMP 基因传递可修复小鼠、大鼠和小型猪的骨不连骨缺损。猪骨髓间充质干细胞(MSCs)的体外转染可在小型猪的椎骨缺损中植入后促进骨再生。从胶原-羟基磷灰石支架中持续释放 VEGF 基因到人类患者的下颌被证明是安全和骨诱导的。总之,基因治疗骨再生的方法正在系统地变得更有效,并在临床相关的动物模型中证明了其概念验证。然而,在通往临床应用的道路上,需要进一步研究来确定各种技术在生物分布、毒性和致瘤性方面的安全性。